Moderna's shares surged 9% after its Phase 3 melanoma study was selected for a prestigious Presidential Symposium slot at the European Society for Medical Oncology congress. This high-profile placement signals strong confidence in the study's potential impact on clinical practice, even though the actual data will be presented on October 24. Merck, a partner in the study, and BioNTech saw smaller gains, indicating the market's focus is mainly on Moderna. Investors await the detailed data presentation and webcast for further insights and potential stock movement.
Moderna's stock price rose sharply by 9.53% to USD 168.72 on Pluang, reflecting strong market interest ahead of its melanoma study presentation. Merck and BioNTech also gained, with Merck up 1.61% at USD 149.12 and BioNTech up 1.31% at USD 97.32. These prices are as of Sep 21, 2026 23:02 WIB.
